Skip to main content

Table 4 Multivariate analysis of factors related to changes from baseline to week 24 in e’ and E/e’ ratio levelsa

From: Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial

Model e’ [cm/s] E/e’
  Change from baseline P valueb R2 Change from baseline P valueb R2
  Beta (95 % CI) Beta (95 % CI)  
Model1—Primary model    0.500    0.609
Baseline 0.525 (0.309 to 0.742) <.0001   0.615 (0.471 to 0.758) <.0001  
Sitagliptin/Voglibose -0.047 (-0.455 to 0.362) 0.8206   0.688 (-0.239 to 1.615) 0.1436  
Age—yr -0.028 (-0.054 to -0.003) 0.0317   0.024 (-0.025 to 0.072) 0.3335  
Without/with TZD 0.547 (0.130 to 0.965) 0.0109   -1.411 (-2.339 to -0.483) 0.0034  
Model2—Add demographic valuesb    0.522    0.641
Baseline 0.520 (0.298 to 0.742) <.0001   0.603 (0.456 to 0.750) <.0001  
Sitagliptin/Voglibose -0.069 (-0.504 to 0.365) 0.7509   0.683 (-0.271 to 1.636) 0.1576  
Age—yr -0.025 (-0.052 to 0.002) 0.0739   0.013 (-0.037 to 0.064) 0.5964  
Female/Male 0.243 (-0.195 to 0.681) 0.2718   -1.114 (-2.092 to -0.137) 0.0261  
BMI (0W) 0.033 (-0.019 to 0.084) 0.2140   -0.037 (-0.155 to 0.081) 0.5306  
SBP (0W) -0.005 (-0.020 to 0.011) 0.5454   -0.002 (-0.036 to 0.031) 0.8917  
Pulse (0W) -0.003 (-0.025 to 0.019) 0.7882   0.022 (-0.028 to 0.071) 0.3911  
Without/with TZD 0.662 (0.216 to 1.108) 0.0042   -1.732 (-2.711 to -0.753) 0.0007  
Model3—Add complicationsb    0.518    0.626
Baseline 0.487 (0.253 to 0.721) <.0001   0.584 (0.425 to 0.744) <.0001  
Sitagliptin/Voglibose 0.018 (-0.426 to 0.462) 0.9362   0.642 (-0.331 to 1.615) 0.1922  
Age—yr -0.031 (-0.057 to -0.004) 0.0228   0.030 (-0.020 to 0.081) 0.2389  
Diabetes complication -0.395 (-1.038 to 0.247) 0.2238   0.721 (-0.799 to 2.241) 0.3473  
Hypertension 0.202 (-0.410 to 0.814) 0.5131   -0.527 (-1.908 to 0.854) 0.4491  
Hyperlipidemia 0.219 (-0.317 to 0.755) 0.4177   -0.886 (-2.086 to 0.313) 0.1450  
Renal disturbance -0.219 (-1.000 to 0.562) 0.5780   0.277 (-1.453 to 2.007) 0.7502  
Without/with TZD 0.511 (0.068 to 0.954) 0.0244   -1.302 (-2.271 to -0.334) 0.0092  
Model4—Add laboratory valuesb    0.525    0.642
Baseline 0.542 (0.314 to 0.770) <.0001   0.615 (0.469 to 0.761) <.0001  
Sitagliptin/Voglibose -0.127 (-0.568 to 0.314) 0.5671   0.669 (-0.314 to 1.651) 0.1790  
Age—yr -0.023 (-0.053 to 0.006) 0.1220   0.029 (-0.027 to 0.084) 0.3045  
WBC (0W) -0.000 (-0.000 to 0.000) 0.7030   0.000 (-0.000 to 0.000) 0.2013  
AST (0W) 0.012 (-0.008 to 0.032) 0.2398   0.003 (-0.040 to 0.046) 0.8871  
BUN (0W) 0.009 (-0.045 to 0.063) 0.7380   -0.019 (-0.139 to 0.101) 0.7498  
Glucagon (0W) -0.001 (-0.012 to 0.010) 0.8296   -0.010 (-0.034 to 0.014) 0.3929  
Adiponectin (0W) -0.017 (-0.049 to 0.016) 0.3067   -0.030 (-0.102 to 0.041) 0.4020  
IVSTh (0W) -0.192 (-1.847 to 1.463) 0.8175   -1.323 (-5.000 to 2.353) 0.4749  
Without/with TZD 0.380 (-0.181 to 0.941) 0.1808   -1.675 (-2.916 to -0.434) 0.0089  
Model5—Add adiponectinc    0.511    0.620
Baseline 0.516 (0.299 to 0.732) <.0001   0.623 (0.480 to 0.766) <.0001  
Sitagliptin/Voglibose -0.080 (-0.490 to 0.330) 0.6991   0.587 (-0.344 to 1.519) 0.2129  
Age—yr -0.025 (-0.051 to 0.001) 0.0637   0.033 (-0.016 to 0.083) 0.1858  
Adiponectin (0W) -0.018 (-0.047 to 0.011) 0.2169   -0.046 (-0.112 to 0.019) 0.1610  
Without/with TZD 0.388 (-0.099 to 0.876) 0.1169   -1.807 (-2.884 to -0.730) 0.0013  
Model6—Remove TZD    0.493    0.560
Baseline 0.480 (0.266 to 0.695) <.0001   0.624 (0.472 to 0.777) <.0001  
Sitagliptin/Voglibose -0.067 (-0.481 to 0.347) 0.7471   0.566 (-0.429 to 1.561) 0.2605  
Age—yr -0.026 (-0.052 to 0.001) 0.0580   0.025 (-0.028 to 0.078) 0.3505  
Adiponectin (0W) -0.030 (-0.055 to -0.005) 0.0187   0.010 (-0.050 to 0.070) 0.7331  
  1. aThe analysis was performed in the full analysis set, with the use of analysis of covariance, WBC denotes white blood cell, AST aspartate transaminase, BUN blood urea nitrogen, IVSTh interventricular septum thickness, and TZD thiazolidinedione
  2. bStatistically significant variables (alpha = 0.05) were selected from measured demographics, complications and laboratory variables with the use of two sample t-tests, according to without/with TZD groups in the full analysis set
  3. cFor e’, without/with TZD was not statistically significant (alpha = 0.05) only if adiponectin was added in the model